Literature DB >> 24146280

Cyclooxygenase 2 promoted the tumorigenecity of pancreatic cancer cells.

Wenjun Li1, Zhengfa Mao, Xin Fan, Lei Cui, Xuqing Wang.   

Abstract

Pancreatic cancer is one of the leading causes of cancer-related death in the world. It is very urgent to find new therapeutic targets and improve the treatment. Cyclooxygenase 2 (Cox2), a regulator of inflammation signaling, has been found to be involved in tumorigenesis of various tumor types. However, its biological functions in pancreatic cancer cells are not fully understood. Here, we found that the expression of Cox2 was elevated in pancreatic cancer tissues compared with that in the paired normal tissues. The over-expression of Cox2 in pancreatic cancer cells promoted cell proliferation and migration, while the knockdown of the expression of Cox2 inhibited the tumorigenesis of pancreatic cancer cells in vitro and in vivo. Mechanistically, Cox2 regulated the expression of multiple genes involved in cell growth, migration, and cell apoptosis. Taken together, our study revealed the pivotal function of Cox2 in pancreatic cancer, and Cox2 might be an important therapeutic target for the treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24146280     DOI: 10.1007/s13277-013-1301-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  15 in total

Review 1.  Genetic progression in the pancreatic ducts.

Authors:  R H Hruban; R E Wilentz; S E Kern
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

Review 2.  Cyclooxygenase isozymes and their gene structures and expression.

Authors:  Tadashi Tanabe; Norimitsu Tohnai
Journal:  Prostaglandins Other Lipid Mediat       Date:  2002-08       Impact factor: 3.072

Review 3.  The role of cyclooxygenases in inflammation, cancer, and development.

Authors:  C S Williams; M Mann; R N DuBois
Journal:  Oncogene       Date:  1999-12-20       Impact factor: 9.867

Review 4.  Role of inflammation in pancreatic carcinogenesis and the implications for future therapy.

Authors:  G Garcea; A R Dennison; W P Steward; D P Berry
Journal:  Pancreatology       Date:  2005-08-16       Impact factor: 3.996

5.  Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer.

Authors:  Allan Lipton; Cynthia Campbell-Baird; Lois Witters; Harold Harvey; Suhail Ali
Journal:  J Clin Gastroenterol       Date:  2010-04       Impact factor: 3.062

6.  Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors.

Authors:  A Kokawa; H Kondo; T Gotoda; H Ono; D Saito; S Nakadaira; T Kosuge; S Yoshida
Journal:  Cancer       Date:  2001-01-15       Impact factor: 6.860

Review 7.  Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia.

Authors:  E Fosslien
Journal:  Crit Rev Clin Lab Sci       Date:  2000-10       Impact factor: 6.250

8.  Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions.

Authors:  R H Hruban; N V Adsay; J Albores-Saavedra; C Compton; E S Garrett; S N Goodman; S E Kern; D S Klimstra; G Klöppel; D S Longnecker; J Lüttges; G J Offerhaus
Journal:  Am J Surg Pathol       Date:  2001-05       Impact factor: 6.394

9.  Cancer incidence and incidence rates in Japan in 2006: based on data from 15 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project.

Authors:  Tomohiro Matsuda; Tomomi Marugame; Ken-Ichi Kamo; Kota Katanoda; Wakiko Ajiki; Tomotaka Sobue
Journal:  Jpn J Clin Oncol       Date:  2011-12-15       Impact factor: 3.019

10.  Inflammatory mechanisms contributing to pancreatic cancer development.

Authors:  Buckminster Farrow; Yuko Sugiyama; Andy Chen; Ekong Uffort; William Nealon; B Mark Evers
Journal:  Ann Surg       Date:  2004-06       Impact factor: 12.969

View more
  9 in total

Review 1.  Environmental immune disruptors, inflammation and cancer risk.

Authors:  Patricia A Thompson; Mahin Khatami; Carolyn J Baglole; Jun Sun; Shelley A Harris; Eun-Yi Moon; Fahd Al-Mulla; Rabeah Al-Temaimi; Dustin G Brown; Annamaria Colacci; Chiara Mondello; Jayadev Raju; Elizabeth P Ryan; Jordan Woodrick; A Ivana Scovassi; Neetu Singh; Monica Vaccari; Rabindra Roy; Stefano Forte; Lorenzo Memeo; Hosni K Salem; Amedeo Amedei; Roslida A Hamid; Leroy Lowe; Tiziana Guarnieri; William H Bisson
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

Review 2.  The impact of low-dose carcinogens and environmental disruptors on tissue invasion and metastasis.

Authors:  Josiah Ochieng; Gladys N Nangami; Olugbemiga Ogunkua; Isabelle R Miousse; Igor Koturbash; Valerie Odero-Marah; Lisa J McCawley; Pratima Nangia-Makker; Nuzhat Ahmed; Yunus Luqmani; Zhenbang Chen; Silvana Papagerakis; Gregory T Wolf; Chenfang Dong; Binhua P Zhou; Dustin G Brown; Anna Maria Colacci; Roslida A Hamid; Chiara Mondello; Jayadev Raju; Elizabeth P Ryan; Jordan Woodrick; A Ivana Scovassi; Neetu Singh; Monica Vaccari; Rabindra Roy; Stefano Forte; Lorenzo Memeo; Hosni K Salem; Amedeo Amedei; Rabeah Al-Temaimi; Fahd Al-Mulla; William H Bisson; Sakina E Eltom
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

3.  Direct Sequencing of Cyclooxygenase-2 (COX-2) Revealed an Intronic Variant rs201231411 in Iranian Patients with Pancreatic Cancer.

Authors:  Ashraf Mohamadkhani; Mohammad Reza Akbari; Reza Ghanbari; Elnaz Naderi; Parisa Rezanejad-Asl; Akram Pourshams
Journal:  Middle East J Dig Dis       Date:  2015-01

4.  NDRG2 controls COX-2/PGE₂-mediated breast cancer cell migration and invasion.

Authors:  Myung-Jin Kim; Hak-Su Kim; Soo-Hwan Lee; Young Yang; Myeong-Sok Lee; Jong-Seok Lim
Journal:  Mol Cells       Date:  2014-09-26       Impact factor: 5.034

5.  Sp1 and COX2 expression is positively correlated with a poor prognosis in pancreatic ductal adenocarcinoma.

Authors:  Junjie Hang; Hai Hu; Junjie Huang; Ting Han; Meng Zhuo; Yangyang Zhou; Lei Wang; Yi Wang; Feng Jiao; Liwei Wang
Journal:  Oncotarget       Date:  2016-05-10

6.  Compound Wumei Powder Inhibits the Invasion and Metastasis of Gastric Cancer via Cox-2/PGE2-PI3K/AKT/GSK3β/β-Catenin Signaling Pathway.

Authors:  Nai-Xia Ma; Wei Sun; Jian Wu; Shen-Lin Liu; Lei Weng; Yang-Qing Liu; Wen-Xiu Pu; Ting-Ting Wu; Xue-Lian Ding; Nan-Guang Huang; Pei-Qiu Zheng; Xi Zou
Journal:  Evid Based Complement Alternat Med       Date:  2017-11-21       Impact factor: 2.629

7.  Lactate production by Staphylococcus aureus biofilm inhibits HDAC11 to reprogramme the host immune response during persistent infection.

Authors:  Cortney E Heim; Megan E Bosch; Kelsey J Yamada; Amy L Aldrich; Sujata S Chaudhari; David Klinkebiel; Casey M Gries; Abdulelah A Alqarzaee; Yixuan Li; Vinai C Thomas; Edward Seto; Adam R Karpf; Tammy Kielian
Journal:  Nat Microbiol       Date:  2020-07-13       Impact factor: 17.745

8.  Solasodine, Isolated from Solanum sisymbriifolium Fruits, Has a Potent Anti-Tumor Activity Against Pancreatic Cancer.

Authors:  Yingchao Fan; Zhumeng Li; Liting Wu; Feng Lin; Jinfeng Shao; Xiaoyan Ma; Yonghua Yao; Wenfang Zhuang; Yuan Wang
Journal:  Drug Des Devel Ther       Date:  2021-04-13       Impact factor: 4.162

9.  Targeting COX-2 potently inhibits proliferation of cancer cells in vivo but not in vitro in cutaneous squamous cell carcinoma.

Authors:  Lipeng Gao; Tim Hua Wang; Champ Peng Chen; Jan Jian Xiang; Xu-Bo Zhao; Rong-Yin Gui; Xin-Hua Liao
Journal:  Transl Cancer Res       Date:  2021-05       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.